These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9689806)

  • 21. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies.
    Galloway ML; Murray D; Moffat DF
    Histopathology; 2006 May; 48(6):767-9. PubMed ID: 16681698
    [No Abstract]   [Full Text] [Related]  

  • 22. [Sarcomatoid mesothelioma--a diagnostic challenge].
    Eiholm S; Meyer CN; Behrendt N
    Ugeskr Laeger; 2010 Sep; 172(39):2670-1. PubMed ID: 20920392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.
    Sherman ME; Mark EJ
    Arch Pathol Lab Med; 1990 Aug; 114(8):845-51. PubMed ID: 2375659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Autopsy case of sarcomatoid malignant pleural mesothelioma].
    Ogura H; Naoki K; Togashi I; Kunikane H; Okamoto H; Hida N; Narita Y; Kase M; Oosawa H; Oomori T; Watanabe K
    Nihon Kokyuki Gakkai Zasshi; 2006 Oct; 44(10):689-94. PubMed ID: 17087333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Closed pleural biopsy to diagnose mesothelioma: dead or alive?
    McLaughlin KM; Kerr KM; Currie GP
    Lung Cancer; 2009 Sep; 65(3):388-9. PubMed ID: 19525027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.
    Zimling ZG; Jørgensen A; Santoni-Rugiu E
    Histopathology; 2012 May; 60(6B):E96-105. PubMed ID: 22394205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
    King J; Thatcher N; Pickering C; Hasleton P
    Histopathology; 2006 Dec; 49(6):561-8. PubMed ID: 17163840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathohistological diagnosis and differential diagnosis.
    Tischoff I; Neid M; Neumann V; Tannapfel A
    Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. My approach to the diagnosis of mesothelial lesions.
    Butnor KJ
    J Clin Pathol; 2006 Jun; 59(6):564-74. PubMed ID: 16731600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathology of diffuse malignant pleural mesothelioma.
    Corson JM
    Semin Thorac Cardiovasc Surg; 1997 Oct; 9(4):347-55. PubMed ID: 9352951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunopathology of diffuse malignant mesothelioma].
    Stosiek P; Goertchen R
    Zentralbl Allg Pathol; 1986; 132(2):119-28. PubMed ID: 2431554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The malignancy grading method is not a reliable assessment of malignancy in mesothelioma.
    Tierney G; Wilkinson MJ; Jones JS
    J Pathol; 1990 Mar; 160(3):209-11. PubMed ID: 2335801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of D2-40 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor.
    Hu Y; Yang Q; McMahon LA; Wang HL; Xu H
    Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):411-3. PubMed ID: 20436345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Verification of the histologic diagnosis of malignant mesothelioma in relation to the binding of an antimesothelial cell antibody.
    Donna A; Betta PG; Jones JS
    Cancer; 1989 Apr; 63(7):1331-6. PubMed ID: 2646006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical utility of diagnostic markers for malignant pleural mesothelioma.
    Grigoriu BD; Grigoriu C; Chahine B; Gey T; Scherpereel A
    Monaldi Arch Chest Dis; 2009 Mar; 71(1):31-8. PubMed ID: 19522163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epithelioid lesions of the serosa.
    Anttila S
    Arch Pathol Lab Med; 2012 Mar; 136(3):241-52. PubMed ID: 22372900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uroplakin is not a reliable immunohistochemical marker for malignant mesothelioma of the pleura.
    Butnor KJ; Ordonez NG
    Appl Immunohistochem Mol Morphol; 2008 Jul; 16(4):326-8. PubMed ID: 18528285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Desmoplastic malignant mesothelioma: two cases and a literature review.
    Hirano H; Maeda H; Sawabata N; Okumura Y; Takeda S; Maekura R; Ito M; Maeda T; Nakane S; Uematsu K
    Med Electron Microsc; 2003 Sep; 36(3):173-8. PubMed ID: 14505061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma.
    Tsuta K; Kato Y; Tochigi N; Hoshino T; Takeda Y; Hosako M; Maeshima AM; Asamura H; Kondo T; Matsuno Y
    Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):126-30. PubMed ID: 19516197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.